There is an urgent need to train the next generation of investigators who have the quality and breadth of experience necessary to conduct interdisciplinary nicotine addiction research. Although there is no agreed upon model for training interdisciplinary scientists, important components include a rich institutional environment (e.g., physical proximity among trainees, mentors, and collaborators from diverse disciplines), an interdisciplinary curriculum (e.g., opportunities to acquire core attitudes, values, and beliefs, knowledge in scientific approaches, and methodological expertise), and competencies (i.e., attitudes, knowledge, and skills).
The Specific Aims of the Center for Interdisciplinary Research on Nicotine Addiction Career Development Core are: (1) To recruit and train 4 postdoctoral fellows who are dedicated to developing a career in nicotine addition. This will be accomplished by providing a multi-disciplinary co-mentored training experience, as well as formal didactic experiences and independent (mentored) research. (2) To facilitate training in nicotine addiction research (and addiction research more broadly) through seminar series, workshops, and assistance with manuscripts and grant applications. (3) To solicit, select and fund promising pilot proposals on nicotine addiction research among postdoctoral fellows and junior faculty to facilitate subsequent grant submissions and career development. While the career development mission of the CIRNA will address nicotine and addiction research more broadly, special emphasis will be placed on research consistent with the CIRNA theme;for example, translational research on nicotine abstinence and pharmacotherapy.
|Ashare, Rebecca L; Lerman, Caryn; Cao, Wen et al. (2016) Nicotine withdrawal alters neural responses to psychosocial stress. Psychopharmacology (Berl) 233:2459-67|
|Forcelli, Patrick A; Turner, Jill R; Lee, Bridgin G et al. (2016) Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology 101:46-56|
|Schnoll, Robert A; Hitsman, Brian; Blazekovic, Sonja et al. (2016) Longitudinal changes in smoking abstinence symptoms and alternative reinforcers predict long-term smoking cessation outcomes. Drug Alcohol Depend 165:245-52|
|Strasser, Andrew A; Souprountchouk, Valentina; Kaufmann, Amanda et al. (2016) Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. Tob Regul Sci 2:352-362|
|Perkins, Kenneth A; Karelitz, Joshua L; Michael, Valerie C et al. (2016) Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. Nicotine Tob Res 18:74-8|
|Ashare, R L; Kimmey, B A; Rupprecht, L E et al. (2016) Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers. Transl Psychiatry 6:e713|
|Lee, Bridgin G; Anastasia, Agustin; Hempstead, Barbara L et al. (2015) Effects of the BDNF Val66Met Polymorphism on Anxiety-Like Behavior Following Nicotine Withdrawal in Mice. Nicotine Tob Res 17:1428-35|
|Falcone, M; Bansal-Travers, M; Sanborn, P M et al. (2015) Awareness of FDA-mandated cigarette packaging changes among smokers of 'light' cigarettes. Health Educ Res 30:81-6|
|Jhanjee, Sonali; Jain, Raka; Jain, Veena et al. (2015) Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India. J Psychoactive Drugs 47:325-30|
|Jain, Raka; Jhanjee, Sonali; Jain, Veena et al. (2015) Biochemical Validation of Self-Reported Smokeless Tobacco Abstinence among Smokeless Tobacco Users: Results from a Clinical Trial of Varenicline in India. J Psychoactive Drugs 47:331-5|
Showing the most recent 10 out of 104 publications